GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47. Following the completion of the sale, the chief executive officer directly owned 14,578 shares of the company's stock, valued at $1,770,789.66. The trade was a 41.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Katherine Stueland also recently made the following trade(s):
- On Tuesday, July 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $105.31, for a total value of $226,837.74.
- On Wednesday, July 9th, Katherine Stueland sold 3,220 shares of GeneDx stock. The stock was sold at an average price of $93.00, for a total transaction of $299,460.00.
- On Tuesday, July 1st, Katherine Stueland sold 9,657 shares of GeneDx stock. The shares were sold at an average price of $90.94, for a total transaction of $878,207.58.
GeneDx Stock Performance
WGS traded up $0.19 during midday trading on Monday, reaching $129.79. The company had a trading volume of 264,041 shares, compared to its average volume of 455,464. The business has a 50-day moving average of $112.57 and a two-hundred day moving average of $93.03. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. GeneDx Holdings Corp. has a 1 year low of $35.88 and a 1 year high of $136.00. The company has a market cap of $3.73 billion, a P/E ratio of 2,595.80 and a beta of 2.03.
GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The company had revenue of $102.69 million during the quarter, compared to analyst estimates of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on WGS. Wall Street Zen raised GeneDx from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Wells Fargo & Company increased their price objective on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Guggenheim reissued a "buy" rating and issued a $115.00 target price (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Finally, Piper Sandler upped their target price on shares of GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Thursday, September 11th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of "Moderate Buy" and an average target price of $104.13.
Read Our Latest Analysis on WGS
Institutional Trading of GeneDx
Several hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. bought a new position in shares of GeneDx during the first quarter valued at approximately $44,614,000. William Blair Investment Management LLC increased its stake in GeneDx by 37.2% in the second quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company's stock worth $150,595,000 after purchasing an additional 442,414 shares during the period. Alliancebernstein L.P. lifted its position in shares of GeneDx by 3,054.5% during the first quarter. Alliancebernstein L.P. now owns 436,900 shares of the company's stock worth $38,694,000 after purchasing an additional 423,050 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of GeneDx by 6,163.1% during the second quarter. Jennison Associates LLC now owns 397,896 shares of the company's stock valued at $36,730,000 after purchasing an additional 391,543 shares during the period. Finally, Westfield Capital Management Co. LP grew its holdings in shares of GeneDx by 164.8% in the second quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company's stock worth $54,388,000 after purchasing an additional 366,711 shares during the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Articles
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
